Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]

View source ↗

Summary

Phase 1 pediatric trial of interleukin-15 and interleukin-21 armored glypican-3–specific CAR T cells for solid tumors, including liver-origin cancers. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embryonal Sarcoma of the Liver
• Hepatoblastoma
• Hepatocellular Carcinoma
• Liposarcoma
• Malignant Rhabdoid Tumor
• Rhabdomyosarcoma
• Wilms Tumor
• Yolk Sac Tumor

Drugs mentioned

• GPC3-targeted CAR T cells (IL-15/IL-21 armored)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Solid Tumor (Excluding CNS), Liver Cell Carcinoma | Phase 1 | Status: RECRUITING